<DOC>
	<DOCNO>NCT01534949</DOCNO>
	<brief_summary>This study design provide initial evidence safety , pharmacokinetics , pharmacodynamics , efficacy support pivotal CT-P10 therapeutic equivalence trial .</brief_summary>
	<brief_title>Provide Initial Evidence Safety , Pharmacokinetics , Pharmacodynamics , Efficacy Support Pivotal CT-P10 Therapeutic Equivalence Trial</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patient histologically proven DLBCL , may represent de novo DLBCL DLBCL arise transform follicular lymphoma chronic lymphocytic leukemia . 2 . Patient relapse refractory CD20positive disease follow previous firstline systemic chemotherapy . Patients fail achieve complete remission previous chemotherapy define refractory , relapse initial complete remission classify relapse . A biopsy must perform confirm diagnosis relapse disease . Tumor tissue within 6 month Day 1 Cycle 1 study treatment use central review . 3 . Patient least 1 measurable tumor mass ( great 1.5 cm long dimension , 1.1 1.5 cm long dimension , great 1.0 cm short axis ) previously irradiate grow since previous irradiation 1 . Patient allergy hypersensitivity murine , chimeric , human , humanized protein . 2 . Patient prior allogeneic ASCT . 3 . Patient receive anticancer therapy within 28 day Day 1 Cycle 1 study treatment 1 prior line chemotherapy , exception receive last dose rituximab within 6 month Day 1 Cycle 1 study treatment undergone prior treatment rituximab .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>DLBCL , Biosimilar</keyword>
</DOC>